Influence of diabetes on the maintenance of sinus rhythm after a successful direct current cardioversion in patients with atrial fibrillation

QJM: An International Journal of Medicine

Volumn 101, Issue 3, 2008, Pages 181-187

  Soran, Handrean ^a   Younis, N ^a   Currie, P ^b   Silas, J ^b   Jones, I R ^b   Gill, G ^c  

^a MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

^b WIRRAL UNIVERSITY TEACHING HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FLECAINIDE; SOTALOL;

ADULT; AGED; ARTICLE; CARDIOVERSION; CONTROLLED STUDY; DIABETES MELLITUS; DIRECT CURRENT; DISEASE DURATION; ELECTROCARDIOGRAM; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINUS RHYTHM;

EID: 39849109823     PISSN: 14602725     EISSN: 14602393     Source Type: Journal    
DOI: 10.1093/qjmed/hcm123     Document Type: Article

References (44)

1. Falk RH. Atrial fibrillation. N Engl J Med 2001; 344:1067-78.
2. Benjamin EJ, Wolf PA, D'Agostino RB, Silbershatz H, Kannel WB, Levy D. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study: Circulation 1998; 98:946-52.
3. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, et al Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) study. JAMA 2001; 285:2370-75.
4. Van Gelder IC, Hagens VE, Bosker HA, Kingma JH, Kamp O, Kingma T, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002; 285:1834-40.
5. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347:1825-33.
6. Gall NP, Murgatroyd MA. Electrical cardioversion for AF-the state of the art. pace 2007; 30:554-67.
7. Masoudi FA, Goldschlager N. The medical management of atrial fibrillation. Cardiol Clin 1997; 15:689-719.
8. Korantzopoulos P, Kolettis TM, Papathanasiou A, Naka KK, Kolios P, Leontaridis I, et al. Propafenone added to ibutilide increases conversion rates of persistent atrial fibrillation. Heart 2006; 92:631-34.
9. Dethy M, Chassat C, Roy D, Mercier LA. Doppler echocardiographic predictors of recurrence of atrial fibrillation after cardioversion. Am J Cardiol 1988; 62:723-26.
10. Dittrich HC, Erickson JS, Schneiderman T, Blacky AR, Savides T, Nicod PH. Echocardiographic and clinical predictors for outcome of elective cardioversion of atrial fibrillation. Am J Cardiol 1989; 63 193-7.
11. Okcun B, Yigit Z, Kucukoglu MS, Mutlu H, Sansoy V, Guzelsoy D, et al Predictors for maintenance of sinus rhythm after cardioversion in patients with nonvalvular atrial fibrillation. Echocardiography 2002; 19:351-57.
12. Van Gelder IC, Crijns HJ, Van Gilst WH, Verwer R, Lie KI. Prediction of uneventful cardioversion and maintenance of sinus rhythm from direct-current electrical cardioversion of chronic atrial fibrillation and flutter. Am J Cardiol 1991; 68:41-6.
13. Movahed MR, Hashemzadeh M, Jamal MM. Diabetes mellitus is a strong, independent risk for atrial fibrillation and flutter in addition to other cardiovascular disease. Int J Cardiol 2005; 105:315-8.
14. Lip GYH, Varughese GI. Diabetes mellitus and atrial fibrillation: perspectives on epidemiological and pathophysiological links. Int J Cardiol 2005; 105:319-21.
15. Ostgren CJ, Merlo J, Rastam L, Lindblad U. Atrial fibrillation and its association with type 2 diabetes and hypertension in a Swedish community. Diabetes Obes Metab 2004; 6:367-74.
16. Sakamoto H, Okamoto E, Imataka K, Ieki K, Fujii J. Prediction of early development of chronic nonrheumatic atrial fibrillation. Jpn Heart J 1995; 36:191-9.
17. Lown B. Electrical reversion of cardiac arrythmias. Br Heart J 1967; 29:469-89.
18. Duytschaever M, Haerynck F, Tavernier R, Jordaens L. Factors influencing long term persistence of sinus rhythm after a first electrical cardioversion for atrial fibrillation. Pacing Clin Electrophysiol 1998; 21:284-87.
19. Volgman AS, Soble JS, Neumann A, Mukhtar KN, Iftikhar F, Vallesteros A, et al. Effect of left atrial size on recurrence of atrial fibrillation after electrical cardioversion: Atrial dimension versus volume. Am J Card Imaging 1996; 10:261-5.
20. Soucier RJ, Mirza S, Abordo MG, Berns E, Dalamagas HC, Hanna A, et al Predictors of conversion of atrial fibrillation after cardiac operation in the absence of class I or III anti-arrhythmic medications. Ann Thorac Surg 2001; 72:694-7.
21. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. Myocardial cell death in human diabetes. Circ Res 2000; 87:1123-32.
22. Haunstetter A, Izumo S. Apoptosis: Basic mechanisms and implications for cardiovascular disease. Circ Res 1998; 82:1111-29.
23. Anversa P, Kajstura J. Myocyte cell death in the diseased heart. Circ Res 1998; 82:1231-3.
24. Anversa P, Leri A, Beltrami CA, Guerra S, Kajstura J. Myocyte death and growth in the failing heart. Lab Invest 1998; 78:767-86.
25. Li B, Setoguchi M, Wang X, Andreoli AM, Leri A, Malhotra A, et al. Insulin-like growth factor-1 attenuates the detrimental impact of nonocclusive coronary artery constriction on the heart. Circ Res 1999; 84:1007-19.
26. Cai L, Li W, Wang G, Guo L, Jiang Y, Kang YJ. Hyperglycemia-induced apoptosis in mouse myocardium: Mitochondrial cytochrome C-mediated caspase-3 activation pathway. Diabetes 2002; 51:1938-48.
27. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation 1991; 83:1849-65.
28. Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: Evidence, mechanisms, and therapeutic implications. Endocr Rev 2004; 25 543-67.
29. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, et al. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001; 50:1414-24.
30. Sechi LA, Griffin CA, Schambelan M. The cardiac reninangiotensin system in STZ-induced diabetes. Diabetes 1994; 43:1180-4.
31. Chen S, Evans T, Mukherjee K, Karmazyn M, Chakrabarti S. Diabetes-induced myocardial structural changes: Role of endothelin-1 and its receptors. J Mol Cell Cardiol 2000; 32:1621-9.
32. Lee AA, Dillmann WH, McCulloch AD, Villarreal FJ. Angiotensin II stimulates the autocrine production of transforming growth factor-beta 1 in adult rat cardiac fibroblasts. J Mol Cell Cardiol 1995; 27 2347-57.
33. Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts, J Mol Cell Cardiol 1997; 29:1947-58.
34. Engelmann MD, Svendsen JH. Inflammation in the genesis and perpetuation of atrial fibrillation. Eur Heart J 2005; 26:2083-92.
35. Sopher SM, Murgatroyd FD, Slade AK, Blankoff I, Rowland E, Ware DE, et al. Low energy internal cardiovesion of atrial fibrillation resistant to transthoracic shocks. Heart 1996; 75:635-8.
36. Frustaci A, Chimenti C, Bellocci F, Morgante E. Russo MA, Maseri A. Histological substrate of atrial biopsies in patients with lone trial fibrillation. Circulation 1997; 96:1180-4.
37. Korantzopoulos P, Kolettis TM, Galaris D, Goudevenos JA. The role of oxidative stress in the pathogenesis and perpetuation of atrial fibrillation. Int J Cardiol 2007; 115:135-43.
38. Chen J, Wasmund SL, Hamdan MH. Back to the future: The role of the autonomic nervous system in atrial fibrillation. Pacing Clin Electrophysiol 2006; 29:413-21.
39. Waller BF, Palumbo PJ, Lie JT, Roberts WC. Status of the coronary arteries at necropsy in diabetes mellitus with onset after age 30 years. Analysis of 229 diabetic patients with and without clinical evidence of coronary heart disease and comparison to 183 control subjects. Am J Med 1980; 69:498-506.
40. Collier A, Matthews DM, Young RJ, Clarke BF. Transient atrial fibrillation precipitated by hypoglycaemia: Two case reports. Postgrad Med J 1987; 63:895-7.
41. Healey JS, Morillo CA, Connolly SJ. Role of the reninangiotensin-aldosterone system in atrial fibrillation and cardiac remodeling. Curr Opin Cardiol 2005; 20:31-7.
42. Madrid AH, Bueno MG, Rebollo JM, Marin D, Pena G, Bernal E, et al. Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106:331-6.
43. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, et al. Use of enalapril to faciligate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24 2090-8.
44. Raitt MH, Volgman AS, Zoble RG, Charbonneau LN, Padder FA, O'Hara GE, et al. Prediction of the recurrence of atrial fibrillation after cardioversion in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. Am Heart J 2006; 151:390-6.